Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bedaquiline + pretomanid + moxifloxacin + pyrazinamide
- Development stage
- Unknown
- Lead developer
- TB Alliance
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BPaMZ is an all-oral, fixed-duration combination regimen for tuberculosis (TB) consisting of four drugs: bedaquiline, pretomanid, moxifloxacin, and pyrazinamide. It is designed to treat both drug-susceptible and drug-resistant forms of pulmonary TB. The regimen has demonstrated high bactericidal activity and the potential to shorten treatment duration compared to standard therapies. Bedaquiline inhibits mycobacterial ATP synthase; pretomanid is a nitroimidazole that disrupts mycobacterial cell wall synthesis under aerobic conditions and releases reactive nitrogen species under anaerobic conditions; moxifloxacin is a fluoroquinolone that inhibits DNA gyrase; pyrazinamide disrupts membrane transport and energy production in Mycobacterium tuberculosis. BPaMZ has been evaluated in pivotal clinical trials such as SimpliciTB for its efficacy and safety in both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB)[1][2][3][7].
- Other names
- Bedaquiline + Pretomanid + Moxifloxacin + Pyrazinamide
02
Targets
Topo IV (Bacterial Topoisomerase IV)DendrinInhAAtpE (ATP synthase subunit c of Mycobacterium tuberculosis)Aspartate decarboxylaseCYTB (Plasmodium falciparum cytochrome bc1 complex (qi site))
Beyond the preview
Go deeper on bedaquiline + pretomanid + moxifloxacin + pyrazinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bedaquiline + pretomanid + moxifloxacin + pyrazinamide.